HIGHLIGHTS
- who: Sophie E. M. Veldhuijzen van Zanten from the Neuroscience Amsterdam, Amsterdam, The Netherlands University Medical Center, Amsterdam, The Netherlands have published the research work: A phase I/II study of gemcitabine during radiotherapy in children with newly diagnosed diffuse intrinsic pontine glioma, in the Journal: (JOURNAL)
- what: The aim of this phase I/II open-label single-arm trial is to investigate the safety tolerability maximum tolerated dose and preliminary efficacy of the potential radiosensitizer gemcitabine administered concomitantly to radiotherapy in children with newly diagnosed (DIPG). Since this study aims for the radiosensitizing effect . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.